SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 10.10 |
| Enterprise Value ($M) | -11.24 |
| Book Value ($M) | -31.63 |
| Book Value / Share | -6.23 |
| Price / Book | -0.32 |
| NCAV ($M) | -31.64 |
| NCAV / Share | -6.24 |
| Price / NCAV | -0.32 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -9.16 |
| Return on Equity (ROE) | -27.68 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.16 |
| Current Ratio | 2.16 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 24.95 |
| Assets | 24.96 |
| Liabilities | 56.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.23 |
| Operating Income | -24.91 |
| Net Income | -166.52 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -29.79 |
| Cash from Investing | -3.65 |
| Cash from Financing | 33.98 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ikarian Capital, LLC | 9.99 | ||
| 13G | Alyeska Investment Group, L.P. | 9.90 | ||
| 13G | Ayrton Capital LLC | 9.90 | ||
| 13D/A | Orbimed Advisors Llc | 19.90 | 25.65 | |
| 13G | Perceptive Advisors Llc | 9.90 | ||
| 13D | Viriom, Inc. | 11.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,608 | 17,092 | 9.41 | |
| 2,785 | 16,790 | 16.59 | |
| 5,015 | 17,085 | 29.35 | |
| 2,524 | 26,468 | 9.54 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TNFA – TNF Pharmaceuticals, Inc. | TNXP – Tonix Pharmaceuticals Holding Corp. |
| TPST – Tempest Therapeutics, Inc. | TSBX – Turnstone Biologics Corp. |
| TTNP – Titan Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io